GFAP and Down syndrome: Furthermore, plasma GFAP and NfL levels were quite robustly related to different disease severity measures (e.g., syndrome diagnosis, cognitive domain scores and MTA score), implying that plasma GFAP and NfL are promising putative biomarker as surrogate outcome measure in monitoring disease severity, and therapeutic effectiveness in clinical trials.